800 related articles for article (PubMed ID: 19405003)
41. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition.
Shoop-Worrall SJW; Verstappen SMM; Baildam E; Chieng A; Davidson J; Foster H; Ioannou Y; McErlane F; Wedderburn LR; Thomson W; Hyrich KL
Ann Rheum Dis; 2017 Aug; 76(8):1381-1388. PubMed ID: 28389553
[TBL] [Abstract][Full Text] [Related]
42. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis.
Tibaldi J; Pistorio A; Aldera E; Puzone L; El Miedany Y; Pal P; Giri PP; De H; Khubchandani R; Chavan PP; Vilaiyuk S; Lerkvaleekul B; Yamsuwan J; Sabui TK; Datta P; Pardeo M; Bracaglia C; Sawhney S; Mittal S; Hassan WA; Elderiny GF; Abu-Zaid MH; Eissa M; Sztajnbok F; das Neves Sztajnbok FC; Russo R; Katsicas MM; Cimaz R; Marrani E; Alexeeva E; Dvoryakovskaya TM; Alsuweiti MO; Alzyoud RM; Kostik M; Chikova I; Minoia F; Filocamo G; Farag Y; Lotfy H; Nasef SI; Al-Mayouf SM; Maggio MC; Magalhaes CS; Gallizzi R; Conti G; Shimizu M; Civino A; Felici E; Giancane G; Ruperto N; Consolaro A; Ravelli A
Rheumatology (Oxford); 2020 Nov; 59(11):3505-3514. PubMed ID: 32829413
[TBL] [Abstract][Full Text] [Related]
43. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
Pratsidou-Gertsi P; Trachana M; Pardalos G; Kanakoudi-Tsakalidou F
Clin Exp Rheumatol; 2010; 28(6):919-22. PubMed ID: 21205467
[TBL] [Abstract][Full Text] [Related]
44. Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study.
Backström M; Tynjälä P; Ylijoki H; Aalto K; Kärki J; Pohjankoski H; Keskitalo P; Sard S; Hietanen M; Lehto H; Kauko T; Vähäsalo P
Rheumatology (Oxford); 2016 Apr; 55(4):615-23. PubMed ID: 26447164
[TBL] [Abstract][Full Text] [Related]
45. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis.
Viola S; Felici E; Magni-Manzoni S; Pistorio A; Buoncompagni A; Ruperto N; Rossi F; Bartoli M; Martini A; Ravelli A
Arthritis Rheum; 2005 Jul; 52(7):2092-102. PubMed ID: 15986372
[TBL] [Abstract][Full Text] [Related]
46. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
47. Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials.
Lim LSH; Lokku A; Pullenayegum E; Ringold S
Arthritis Care Res (Hoboken); 2023 Jun; 75(6):1238-1249. PubMed ID: 36651601
[TBL] [Abstract][Full Text] [Related]
48. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH;
Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582
[TBL] [Abstract][Full Text] [Related]
49. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
50. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
[TBL] [Abstract][Full Text] [Related]
51. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study.
Susic GZ; Stojanovic RM; Pejnovic NN; Damjanov NS; Soldatovic II; Jablanovic DB; Sefik Bukilica MN
Clin Exp Rheumatol; 2011; 29(2):337-44. PubMed ID: 21385554
[TBL] [Abstract][Full Text] [Related]
52. Association of disease activity using SDAI and DAS28, but not JADAS-27, with subsequent changes in physical function in adult patients with juvenile idiopathic arthritis.
Miyamae T; Inoue E; Tanaka E; Kawabe T; Ikari K; Harigai M
Mod Rheumatol; 2023 Apr; 33(3):588-593. PubMed ID: 35713223
[TBL] [Abstract][Full Text] [Related]
53. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.
Aletaha D; Nell VP; Stamm T; Uffmann M; Pflugbeil S; Machold K; Smolen JS
Arthritis Res Ther; 2005; 7(4):R796-806. PubMed ID: 15987481
[TBL] [Abstract][Full Text] [Related]
54. [Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis].
Horneff G; Minden K; Foell D; Klotsche J; Tenbrock K;
Z Rheumatol; 2024 Feb; 83(1):15-27. PubMed ID: 38157052
[TBL] [Abstract][Full Text] [Related]
55. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis.
Selvaag AM; Aulie HA; Lilleby V; Flatø B
Ann Rheum Dis; 2016 Jan; 75(1):190-5. PubMed ID: 25362042
[TBL] [Abstract][Full Text] [Related]
56. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index.
Aletaha D; Martinez-Avila J; Kvien TK; Smolen JS
Ann Rheum Dis; 2012 Jul; 71(7):1190-6. PubMed ID: 22454398
[TBL] [Abstract][Full Text] [Related]
57. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T
J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463
[TBL] [Abstract][Full Text] [Related]
58. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
59. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.
Magni-Manzoni S; Ruperto N; Pistorio A; Sala E; Solari N; Palmisani E; Cugno C; Bozzola E; Martini A; Ravelli A
Arthritis Rheum; 2008 Aug; 59(8):1120-7. PubMed ID: 18668599
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
